KMR Group
Companies seeking to improve global clinical trial timelines have found opportunities through careful assessment of the span from protocol approval to start of randomization in each region. One analysis performed as part of KMR Group's Enrollment Productivity Study assesses how long it takes each company to start in each region.
Although it may vary for certain therapy areas, North America has the shortest start-up cycle time at 4.1 months. Japan is also shorter than average at 5.4 months.
Study start-up cycle time by region.
A major challenge—and a major opportunity—presents itself after the typical first patient is enrolled in the initial region. Some companies have made synchronized start up across regions a priority, yielding improvements in performance for the overall global trials.
Emerging market regions (e.g., Latin America, Eastern Europe, and Asia) require more than twice the time to begin enrollment, compared to the shortest first-region cycle times. This can be due in part to the practice at some companies in the industry to begin enrollment in regions in serial fashion, one after the other. One of the complicating factors in the emerging market regions is that regulatory requirements in certain countries are more difficult to meet.
—KMR Group, https://kmrgroup.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.